Donanemab-Azbt 350 mg/20 mL Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 350 mg/20 mL
Reference Brands: Kisunla(USA)
Category: Neurology
Donanemab-azbt is a humanized immunoglobulin G1 monoclonal antibody directed against insoluble, N‑truncated pyroglutamate amyloid‑beta found in amyloid plaques in the brains of patients with Alzheimer’s disease. Its mechanism involves binding to these amyloid plaques and facilitating their removal (via microglial-mediated phagocytosis), thereby reducing amyloid burden in the brain. Use of donanemab has been shown to slow cognitive and functional decline in adults with early symptomatic Alzheimer’s disease (mild cognitive impairment or mild dementia) who have confirmed amyloid pathology.
Donanemab-Azbt — third party manufacturing & bulk supply
Donanemab-Azbt 350 mg/20 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Donanemab-Azbt listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Donanemab-Azbt →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Donanemab-azbt is an experimental drug under investigation for the treatment of Alzheimer’s disease. It is designed to target and remove amyloid-beta plaques in the brain, which are associated with the progression of Alzheimer’s.
It is made from a humanized monoclonal antibody that specifically binds to modified amyloid-beta proteins in the brain.
There is currently no approved trade name, as the drug is still in clinical trials.
Donanemab is developed by Eli Lilly and Company.
The generic name is donanemab-azbt.
No brand name has been assigned yet.
It is manufactured in specialized biopharmaceutical facilities, primarily in the USA, under controlled conditions for clinical development.
Related Products
Valproic Acid
Strength:
125 mg/mL, 200 mg, 250 mg, 300 mg, 500 mg, 100 mg/mL
Form: Tablet / Capsule/ Injection / Oral syrup
Reference Brands: Depakene (USA), Depakine (EU/LATAM), Valprol (India)
View Details
Quick Response Guaranteed | Verified Suppliers
